Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Apr. 30, 2014
Apr. 30, 2013
Apr. 30, 2014
Apr. 30, 2013
Revenues:        
Clinical laboratory services $ 14,542 $ 13,384 $ 43,250 $ 41,881
Product revenues 8,707 8,265 24,424 24,574
Royalty and license fee income 729 949 3,366 3,982
Total revenues 23,978 22,598 71,040 70,437
Operating expenses:        
Cost of clinical laboratory services 9,784 9,331 28,785 28,466
Cost of product revenues 3,800 4,219 11,511 12,546
Research and development 849 989 2,498 2,968
Selling, general, and administrative 10,605 11,032 31,217 33,340
Provision for uncollectible accounts receivable 684 928 2,468 3,857
Legal fee expense 1,911 1,708 4,788 4,850
Legal settlements, net (3,100)   (3,100)  
Total operating expenses 24,533 28,207 78,167 86,027
Operating loss (555) (5,609) (7,127) (15,590)
Other income (expense):        
Interest (47) (10) (161) (25)
Other 10 25 85 81
Foreign currency gain 144 (214) 460 119
Loss before income taxes (448) (5,808) (6,743) (15,415)
(Provision) benefit for income taxes (7) 38 (65) 280
Net loss $ (455) $ (5,770) $ (6,808) $ (15,135)
Net loss per common share:        
Basic and diluted (in Dollars per share) $ (0.01) $ (0.15) $ (0.16) $ (0.38)
Weighted average common shares outstanding:        
Basic and diluted (in Shares) 43,243 39,553 42,062 39,381